Form 4: Spruce Biosciences Director Acquires Stock Options

Camilla V. Simpson, a director of Spruce Biosciences, acquired stock options for 30,000 shares on May 22, 2024.

Summary

• On May 22, 2024, Camilla V. Simpson, a director of Spruce Biosciences, acquired stock options for 30,000 shares.
• The exercise price of the stock options is $0.7511.
• The options vest on the first anniversary of the grant date or fully vest by the date of the company's 2025 annual stockholder meeting, subject to continuous service.
• The options also vest in full upon a Change in Control as defined in the 2020 Equity Incentive Plan.
• The expiration date for the options is May 21, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring stock options can be seen as a sign of confidence, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder confidence.

Key Dates